Clinical Trials Logo

Clinical Trial Summary

This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol. The evidence generated from this project will be key to develop future strategies regarding cholera vaccine use in endemic settings, including places with higher burden in terms of cholera mortality.


Clinical Trial Description

The project will comprise three different components: 1. Clinical cholera surveillance to measure cholera diseases incidence in selected African hotspots targeted by vaccination. 2. Serial serological surveys to measure the prevalence of recent cholera infection (within the last 12 months). 3. Identification and follow up of individuals with positive V. cholerae shedding (symptomatic or asymptomatic) among sero-survey participants and among household members of cholera confirmed cases. The present protocol relates to the setup of clinical surveillance and the follow up of individuals with positive V. cholerae shedding identified through clinical surveillance, in DRC. This protocol will allow us to assess if a large vaccination campaign reaching high coverage in cholera hotspot in Africa can allow sustained control of cholera for at least two years, by fulfilling the following specific objectives: - To measure cholera incidence rates following the mass vaccination campaign in two cholera hotspots in Africa. - To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. - To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household. - To describe the global genetic diversity of V. cholerae strains in the study areas and within households affected by cholera. - To develop sustainable surveillance methods that could be applied in other hotspots in Africa and elsewhere aiming to monitor the impact of the cholera control program. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04853186
Study type Observational
Source Epicentre
Contact Anais BROBAN
Phone +33140215429
Email [email protected]
Status Recruiting
Phase
Start date May 11, 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT01895855 - Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Phase 3
Completed NCT01339845 - Introduction of Cholera Vaccine in Bangladesh N/A
Recruiting NCT02928341 - Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo N/A
Completed NCT02864433 - Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Completed NCT04150250 - Cholera Anti-Secretory Treatment Trial Phase 2
Terminated NCT00624975 - Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Phase 2
Completed NCT00226616 - Zinc Supplementation in Cholera Patients Phase 3
Completed NCT03373669 - Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Phase 4
Completed NCT02100631 - A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Phase 3
Completed NCT02094586 - A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Phase 3
Completed NCT01823939 - PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Phase 1
Completed NCT01365442 - Pilot Introduction of Oral Cholera Vaccine in Orissa, India N/A
Completed NCT00128011 - Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Phase 2
Completed NCT00672308 - Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Phase 2
Completed NCT00142272 - Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Phase 3
Not yet recruiting NCT04760236 - Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shancholâ„¢ in Nepalese Phase 3
Recruiting NCT04816552 - Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change N/A
Not yet recruiting NCT02502331 - Safety and Immunogenicity of a New Formulation of Euvichol® Phase 3
Completed NCT01949675 - A Study of Two Doses of Oral Cholera Vaccine (Shancholâ„¢) in Subjects Aged 1 Year and Older in the Philippines Phase 4
Unknown status NCT01508507 - Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine N/A